Navigation Links
PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
Date:7/29/2009

INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets Healthcare Conference in New York City on Wednesday, August 5, 2009 at 3:30 p.m. Eastern Time.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and click "Investors." Please connect to the Web site at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay will be available at www.pdl.com starting approximately three hours after completion of the webcast.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
2. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
5. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
6. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
7. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
8. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
9. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
10. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
11. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Partnering to fuel Philadelphia,s innovative ... Southeastern Pennsylvania (" Ben Franklin "); ... Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... million funding initiative over a four year period to ... a burgeoning economic vitality in digital health, Ben ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, ... escalation and expansion clinical trial for its lead drug candidate, AC0010, at the ... the trial was to determine the safety, antitumor activity, and recommended phase II ...
(Date:12/7/2016)... ... 07, 2016 , ... Huffman Engineering, Inc. , a ... Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company recognized ... Integrator Partner certification gives customers confidence that our engineers are fully trained and ...
(Date:12/7/2016)... - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused ... for the treatment of cancer, today announced that ... Program with Cytovance Biologics ( Oklahoma City, ... product. Supported by recent positive interim clinical results ... cancer patients, OncoQuest has engaged Cytovance to establish ...
Breaking Biology Technology:
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
Breaking Biology News(10 mins):